Clinical Trials Sponsored by CAMP4 Therapeutics Corporation

Total 77 results

CAMP4 Therapeutics Corporation

Recruiting

Study of CMP-CPS-001 in Healthy Volunteers

Healthy Volunteers

Australia
Taivex Therapeutics Corporation

Recruiting

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Lymphoma | Advanced Solid Tumor

Taiwan
Carmell Therapeutics Corporation

Withdrawn

Multiregion BHA in Open Tibia Fractures

Tibial Fractures
Celltex Therapeutics Corporation

No longer available

Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

Alzheimer Disease
Chase Therapeutics Corporation

Active, not recruiting

A Study to Evaluate in Patients With Parkinsonian Type Disorders

Idiopathic Parkinson Disease

United States
Taivex Therapeutics Corporation

Terminated

Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Targanta Therapeutics Corporation

Completed

A Study for Patients With Complicated Skin and Skin Structure Infections (SIMPLIFI)

Wounds and Injuries | Streptococcal Infections | Abscess | Cellulitis | Staphylococcal Skin Infections

United States, Australia, India, Italy, Romania, Ukraine
Celltex Therapeutics Corporation

Not yet recruiting

Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)

Covid19 | Corona Virus Infection
Carmell Therapeutics Corporation

Withdrawn

Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle Arthrodesis

Foot Deformities
Carmell Therapeutics Corporation

Withdrawn

Bone Healing Accelerant Versus Standard of Care for Open Tibia Fractures

Tibial Fractures

United States
BriaCell Therapeutics Corporation

Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC)

Breast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage Cancer

United States
ABM Therapeutics Corporation

Recruiting

Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.

Advanced Solid Tumor | RAS Mutation | NF1 Mutation | RAF Mutation

United States
Taivex Therapeutics Corporation

Recruiting

Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Taiwan
Celltex Therapeutics Corporation

Not yet recruiting

Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis (AdMSCs)

Osteoarthritis, Knee | Osteoarthritis, Hip | Osteoarthritis Shoulder

United States
Celltex Therapeutics Corporation

Not yet recruiting

Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19

COVID-19
Celltex Therapeutics Corporation

Not yet recruiting

Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis

Rheumatoid Arthritis
ABM Therapeutics Corporation

Terminated

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Advanced Solid Tumor | BRAF V600 Mutation

United States
Taivex Therapeutics Corporation

Active, not recruiting

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Chase Therapeutics Corporation

Active, not recruiting

A Study in Patients With Major Depressive Disorder

Major Depressive Disorder (MDD)

United States
Taivex Therapeutics Corporation

Completed

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
CuraGen Corporation

Completed

Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

Stomatitis

United States
CuraGen Corporation

Completed

Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
BriaCell Therapeutics Corporation
LumaBridge

Enrolling by invitation

Combination Study of SV-BR-1-GM With Retifanlimab

Breast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic

United States
CuraGen Corporation

Completed

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Stomatitis | Oral Mucositis

United States
CuraGen Corporation

Completed

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Unresectable Stage III or Stage IV Melanoma

United States
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) (INFUSE-NSLR)

Healthy

United States
Baxter Healthcare Corporation
Halozyme Therapeutics

Withdrawn

Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED) (INFUSE-TM)

Dehydration
3E Therapeutics Corporation
ORA, Inc.

Completed

Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis

Seasonal Allergic Rhinitis
Baxter Healthcare Corporation
Halozyme Therapeutics

Completed

Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration (INFUSE-Cftrx)

Healthy
Baxter Healthcare Corporation
Halozyme Therapeutics

Completed

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT)

Dehydration

United States
Antengene Therapeutics Limited

Terminated

A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma (TEACH)

Solid Tumor, Non-Hodgkin's Lymphoma

China, Taiwan
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Subcutaneous Rehydration Compared to Intravenous Rehydration (PEDs-II)

Dehydration

United States
Baxter Healthcare Corporation
Halozyme Therapeutics

Terminated

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A) (INFUSE-AT1A)

Dehydration

United States
Incyte Corporation
Mirati Therapeutics Inc.

Recruiting

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Advanced Solid Tumors

United States, Canada, Spain, United Kingdom, Italy
Antengene Therapeutics Limited

Terminated

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Hepatocellular Carcinoma

Korea, Republic of, Taiwan, China
Abeona Therapeutics, Inc
Genaera Corporation

Completed

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Diabetic Foot Ulcers

United States
Abeona Therapeutics, Inc
Genaera Corporation

Completed

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Diabetic Foot Ulcers

United States
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed or Refractory Peripheral T-cell Lymphoma

Taiwan
BioXcel Therapeutics Inc
Cognitive Research Corporation

Completed

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal (RELEASE)

Opioid Withdrawal

United States
BioXcel Therapeutics Inc
Cognitive Research Corporation

Completed

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia (TRANQUILITY)

Dementia | Agitation,Psychomotor

United States
BioXcel Therapeutics Inc
Cognitive Research Corporation

Completed

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder (SERENITY II)

Bipolar Disorder | Agitation,Psychomotor | Agitation Associated With Bipolar Disorder

United States
BioXcel Therapeutics Inc
Cognitive Research Corporation

Completed

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

Dementia | Agitation

United States
BioXcel Therapeutics Inc
Cognitive Research Corporation

Terminated

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Dementia | Agitation

United States
BioXcel Therapeutics Inc
Cognitive Research Corporation

Completed

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

Schizophrenia | Agitation

United States
BioXcel Therapeutics Inc
Cognitive Research Corporation

Withdrawn

Study of BXCL501 In Agitation Associated With Delirium in ICU Patients

Delirium | Agitation

United States
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
BioXcel Therapeutics Inc
Cognitive Research Corporation

Recruiting

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Schizophrenia | Bipolar Disorder I | Schizo-Affective Disorder | Schizophreniform; Schizophrenic | Bipolar Disorder II

United States
BioXcel Therapeutics Inc
Cognitive Research Corporation

Terminated

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Dementia | Agitation

United States
BioXcel Therapeutics Inc
Cognitive Research Corporation

Completed

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia (SERENITY I)

Schizophrenia | Schizoaffective Disorder | Agitation | Schizo Affective Disorder | Schizophreniform Disorders

United States
Sorrento Therapeutics, Inc.
Kimberly-Clark Corporation

Completed

Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002) (KCC-SMT-002)

Migraine Disorders

United States

Clinical Trials Sponsored by CAMP4 Therapeutics Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations